Petosemtamab + Pembrolizumab for Lung Cancer

Recruiting at 2 trial locations

Overseen By Alejandro Ricart, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Merus N.V.

Must not be taking: PD-(L)1 inhibitors

Disqualifiers: Untreated CNS metastases, Prior malignancies, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 6-12 months

180 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.

Are You a Good Fit for This Trial?

Adults with metastatic non-small cell lung cancer, either squamous or non-squamous type, can join this trial. They must have normal magnesium and calcium levels, be able to follow study rules and use contraception if needed. Participants should be over 18 years old with a measurable tumor, in good physical condition (ECOG 0 or 1), expected to live at least 12 weeks, have proper blood counts and kidney/liver function.

Inclusion Criteria

I agree to use effective birth control during the study.

I can sign consent and follow study rules, including birth control needs.

I am 18 years old or older.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive petosemtamab in combination with Pembrolizumab as first-line treatment for metastatic non-small cell lung cancer

Up to 6-12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 4.5 years

What Are the Treatments Tested in This Trial?

Interventions

• Petosemtamab

Trial Overview

The trial is testing the effectiveness of a new treatment combination: Petosemtamab plus Pembrolizumab for patients who haven't been treated before for their lung cancer. The goal is to see how well these drugs work together as an initial therapy.

How Is the Trial Designed?

Group I: First line squamous non-small cell lung cancer patients Experimental Treatment 1 Intervention

Group II: First line non-squamous non-small cell lung cancer patients Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Merus N.V.

Lead Sponsor

Trials

10

Recruited

2,700+